null The European Pharmacopoeia Commission elects its two new Vice Chairs

EDQM Strasbourg, France 10/08/2022
Dr Eugenia Cogliandro (first Vice Chair) and Dr Marija Malesevic (second Vice Chair)

Dr Eugenia Cogliandro (first Vice Chair) and Dr Marija Malesevic (second Vice Chair)

The European Pharmacopoeia (Ph. Eur.) Commission is pleased to announce the nomination of two new Vice Chairs, elected at its 173rd session held on 22 and 23 June 2022. Dr Eugenia Cogliandro (first Vice Chair) and Dr Marija Malesevic (second Vice Chair), replace outgoing Vice Chairs Prof. S. Cañigueral Folcará (elected Chair at the March session of the Commission) and Dr G. Benkovic, whose dedication and support for the work of the Ph. Eur. over their three-year mandate have been invaluable.

Elected first Vice Chair, Eugenia Cogliandro, member of the Ph. Eur. Commission since 2009, has been a quality assessor for more than 20 years and thus has extensive experience and knowledge of the European regulatory system. Highlighting the importance of playing an active role in the Ph. Eur. family, she feels that “The European Pharmacopoeia promotes public health by providing common quality standards for the safe use of medicines. It is widely used on an international level, not only by the Member States which are part of the European Pharmacopeia Convention, but worldwide: this global impact along with the opportunity to contribute to the basic human right of access to good quality medicines and healthcare, make me feel very pleased and honoured to offer my experience, both in the pharmacopoeial and regulatory fields, through the position of Vice Chair of the European Pharmacopoeia Commission”.

Second Vice Chair Marija Malesevic has been a member of the Ph. Eur. Commission since 2011 and has also gained valuable insight into the inner workings of the pharmacopoeia through her activity as the Chair of Group P4 (group of experts in charge of drafting and revising monographs in the field of single-source active substances, excipients and medicinal products with chemically defined active substances). After being Head of the Chemical Laboratory at the Medicines and Medical Devices Agency of Serbia, in 2010 she was appointed – and remains – responsible person for market surveillance quality control and pharmacopoeia affairs at the Agency. Highlighting the advantages of working with the Ph. Eur. Commission, in her view “European Pharmacopoeia public standards are of huge importance to contributing to one of the basic human rights: that of offering access to good quality medicines and healthcare. Working for the European Pharmacopoeia is a great privilege because you are at the source of the latest information, no matter the field of pharmacy you are dealing with.”

The European Pharmacopoeia congratulates the two new Vice Chairs on their appointment and wishes them every success in their new duties.

See also: